Organigram Global (NASDAQ:OGI) & Becton, Dickinson and Company (NYSE:BDX) Financial Analysis

Organigram Global (NASDAQ:OGI – Get Free Report) and Becton, Dickinson and Company (NYSE:BDX – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, earnings and profitability.

Institutional & Insider Ownership

34.6% of Organigram Global shares are held by institutional investors. Comparatively, 87.0% of Becton, Dickinson and Company shares are held by institutional investors. 0.1% of Organigram Global shares are held by insiders. Comparatively, 0.4% of Becton, Dickinson and Company shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Organigram Global has a beta of 1.55, suggesting that its stock price is 55% more volatile than the S&P 500. Comparatively, Becton, Dickinson and Company has a beta of 0.22, suggesting that its stock price is 78% less volatile than the S&P 500.

Profitability

This table compares Organigram Global and Becton, Dickinson and Company’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Organigram Global 28.14% -13.39% -8.67%
Becton, Dickinson and Company 5.66% 14.90% 7.09%

Analyst Recommendations

This is a breakdown of recent ratings for Organigram Global and Becton, Dickinson and Company, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Organigram Global 1 0 2 0 2.33
Becton, Dickinson and Company 1 8 8 1 2.50

Becton, Dickinson and Company has a consensus target price of $197.47, indicating a potential downside of 9.40%. Given Becton, Dickinson and Company’s stronger consensus rating and higher possible upside, analysts plainly believe Becton, Dickinson and Company is more favorable than Organigram Global.

Earnings and Valuation

This table compares Organigram Global and Becton, Dickinson and Company”s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Organigram Global $185.07 million 0.63 -$17.70 million $0.46 1.80
Becton, Dickinson and Company $19.46 billion 3.09 $1.15 billion $4.14 52.64

Becton, Dickinson and Company has higher revenue and earnings than Organigram Global. Organigram Global is trading at a lower price-to-earnings ratio than Becton, Dickinson and Company, indicating that it is currently the more affordable of the two stocks.

Summary

Becton, Dickinson and Company beats Organigram Global on 13 of the 15 factors compared between the two stocks.

About Organigram Global

(Get Free Report)

Organigram Global Inc. is a Canadian cannabis company that cultivates, processes and sells cannabis and cannabinoid products. Its offerings include dried flower, pre-rolls, edibles, vape products, concentrates and cannabis-infused beverages, sold under brands such as Edison, SHRED, Big Bag O’ Buds and BOXHOT. The company traces its roots to Organigram, a licensed cannabis producer established in New Brunswick. It expanded its portfolio and manufacturing capabilities through acquisitions, including the 2024 purchase of Canadian cannabis company Motif Labs.

About Becton, Dickinson and Company

(Get Free Report)

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops and manufactures products used in healthcare, clinical laboratories and life sciences research. Founded in 1897, the company has a long history of producing medical devices and supplies. BD’s products include syringes, needles, infusion systems and medication-management technologies, as well as equipment and supplies for collecting and processing clinical specimens. The company also provides diagnostic systems, laboratory instruments and tools used in areas such as cell analysis and biomedical research.

Receive News & Ratings for Organigram Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organigram Global and related companies with MarketBeat.com's FREE daily email newsletter.